Depleting CD8+ T cells or neutralizing TNFα has been found to ameliorate HCC progression in mice receiving anti-PD1, thus suggesting a rationale for stratifying patients with HCC according to etiology before immune checkpoint-based immunotherapy9,10. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.